{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:21:45Z","timestamp":1783401705505,"version":"3.54.6"},"reference-count":69,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031283","name":"Sanofi, France","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031283","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2020,3,3]]},"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Non-alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal results of liver function tests. Earlier research showed that polyenylphosphatidylcholine (PPC) has hepatoprotective effects and thus can be used for the treatment of NAFLD and the prevention of its progression. Accordingly, the aim of this observational study was to evaluate if PPC administered as adjunctive therapy in routine clinical practice can effectively improve liver function tests of NAFLD in Russian patients with associated metabolic comorbidities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A total of 2843 adult patients with newly diagnosed NAFLD, who had a least one of four comorbidities, namely, overweight\/obesity, hypertension, type 2 diabetes mellitus, and hypercholesterolaemia, and who were prescribed 1.8\u2009g\/day of PPC as an adjunctive treatment to standard care, were enrolled during 2015\u20132016. Laboratory data were collected at baseline and 12 and 24 weeks of the study, and included liver function tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT)), fasting plasma glucose, and lipid profile.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 2263 patients (79.6%) had at least two metabolic comorbidities associated with NAFLD, and overweight\/obesity was the most common comorbidity reported in 2298 (80.8%) patients. At 24 weeks, there was a significant decrease in liver enzyme levels (all p&lt;0.001 compared with baseline). Across the four comorbidity subgroups, there was a mean drop of ALT levels ranging from 19.7 to 22.0\u2009U\/L, AST from 16.9 to 18.4\u2009U\/L, and GGT from 17.2 to 18.7\u2009U\/L. Similar findings were reported in subgroups with either one, two, three, or four comorbidities, with a significant decrease in liver enzyme levels ranging from 18.4 to 22.4\u2009U\/L for ALT, 14.8 to 18.7\u2009U\/L for AST, and 15.5 to 19.5\u2009U\/L for GGT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Adjuvant treatment with PPC resulted in consistent improvements in liver enzymes in patients with newly diagnosed NAFLD and associated metabolic comorbidities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00063622\">NCT00063622<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2019-000368","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T07:05:28Z","timestamp":1585292728000},"page":"e000368","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct00063622","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Igor V","family":"Maev","sequence":"first","affiliation":[{"name":"AI Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksey A","family":"Samsonov","sequence":"additional","affiliation":[{"name":"AI Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liudmila K","family":"Palgova","sequence":"additional","affiliation":[{"name":"Clinical Research and Educational Center in Gastroenterology and Hepatology, Saint Petersburg State University, Saint-Petersburg, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chavdar S","family":"Pavlov","sequence":"additional","affiliation":[{"name":"IM Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena N","family":"Shirokova","sequence":"additional","affiliation":[{"name":"IM Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena I","family":"Vovk","sequence":"additional","affiliation":[{"name":"AI Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-7980","authenticated-orcid":false,"given":"Kirill M","family":"Starostin","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sanofi-Aventis SA, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"key":"2025073013320078000_7.1.e000368.1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i6.846"},{"key":"2025073013320078000_7.1.e000368.2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i34.12082"},{"key":"2025073013320078000_7.1.e000368.3","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12291"},{"key":"2025073013320078000_7.1.e000368.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-World data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"Alexander","year":"2018","journal-title":"BMC Med"},{"key":"2025073013320078000_7.1.e000368.5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajg.2015.09.001","article-title":"Essential phospholipids as a supportive adjunct in the management of patients with NAFLD","volume":"16","author":"Dajani","year":"2015","journal-title":"Arab J Gastroenterol"},{"key":"2025073013320078000_7.1.e000368.6","doi-asserted-by":"publisher","DOI":"10.1381\/096089203322190853"},{"key":"2025073013320078000_7.1.e000368.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04698.x"},{"key":"2025073013320078000_7.1.e000368.8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MCG.0000000000000116","article-title":"World gastroenterology organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"48","author":"LaBrecque","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"2025073013320078000_7.1.e000368.9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1155\/2014\/675409","article-title":"Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey","volume":"28","author":"Sebastiani","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2025073013320078000_7.1.e000368.10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4103\/2230-8210.163172","article-title":"Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes","volume":"19","author":"Sanyal","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"key":"2025073013320078000_7.1.e000368.11","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(01)80321-8","article-title":"Nonalcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the U.S. population","volume":"120","author":"Clark","year":"2001","journal-title":"Gastroenterology"},{"key":"2025073013320078000_7.1.e000368.12","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2013-100403"},{"key":"2025073013320078000_7.1.e000368.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.03.020"},{"key":"2025073013320078000_7.1.e000368.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4596","article-title":"Non-Alcoholic fatty liver disease","volume":"349","author":"Sattar","year":"2014","journal-title":"BMJ"},{"key":"2025073013320078000_7.1.e000368.15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300604"},{"key":"2025073013320078000_7.1.e000368.16","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2017.00021"},{"key":"2025073013320078000_7.1.e000368.17","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.216077"},{"key":"2025073013320078000_7.1.e000368.18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20466"},{"key":"2025073013320078000_7.1.e000368.19","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.107.147538"},{"key":"2025073013320078000_7.1.e000368.20","doi-asserted-by":"publisher","DOI":"10.1002\/cld.65"},{"key":"2025073013320078000_7.1.e000368.21","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/827172"},{"key":"2025073013320078000_7.1.e000368.22","doi-asserted-by":"crossref","DOI":"10.4155\/fsoa-2017-0083","article-title":"Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression","volume":"4","author":"Nallagangula","year":"2018","journal-title":"Future Sci OA"},{"key":"2025073013320078000_7.1.e000368.23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20092"},{"key":"2025073013320078000_7.1.e000368.24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-Dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Leuschner","year":"2010","journal-title":"Hepatology"},{"key":"2025073013320078000_7.1.e000368.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.520"},{"key":"2025073013320078000_7.1.e000368.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929"},{"key":"2025073013320078000_7.1.e000368.27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.5370"},{"key":"2025073013320078000_7.1.e000368.28","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c5702","article-title":"Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials","volume":"341","author":"Sch\u00fcrks","year":"2010","journal-title":"BMJ"},{"key":"2025073013320078000_7.1.e000368.29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1437"},{"key":"2025073013320078000_7.1.e000368.30","unstructured":"Pharmaceuticals I . Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH [Press release]. April 11, 2019. Available: http:\/\/ir.interceptpharma.com\/news-releases\/news-release-details\/intercept-reports-additional-positive-data-regenerate-first [Accessed 4 Dec 2019]."},{"key":"2025073013320078000_7.1.e000368.31","unstructured":"Sciences G . Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) [Press release]. February 11, 2019. Available: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2019\/2\/gilead-announces-topline-data-from-phase-3-stellar4-study-of-selonsertib-in-compensated-cirrhosis-f4-due-to-nonalcoholic-steatohepatitis-nash [Accessed 4 Dec 2019]."},{"key":"2025073013320078000_7.1.e000368.32","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0437-3"},{"key":"2025073013320078000_7.1.e000368.33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0973-3930.26859","article-title":"Effect of essentiale in diabetic subjects with Non - Alcoholic fatty liver","volume":"25","author":"Poongothai","year":"2005","journal-title":"Int J Diabetes Dev Ctries"},{"key":"2025073013320078000_7.1.e000368.34","first-page":"105","article-title":"Essential phospholipids in fatty liver: a scientific update","volume":"9","author":"Gundermann","year":"2016","journal-title":"Clin Exp Gastroenterol"},{"key":"2025073013320078000_7.1.e000368.35","first-page":"735","article-title":"An observational study of Essentiale-L in the treatment of patients with fatty liver disease","volume":"23","author":"Padma","year":"2013","journal-title":"Indian Journal of Clinical Practice"},{"key":"2025073013320078000_7.1.e000368.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(94)95023-7"},{"key":"2025073013320078000_7.1.e000368.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1997.tb03776.x"},{"key":"2025073013320078000_7.1.e000368.38","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-004-0027-0"},{"key":"2025073013320078000_7.1.e000368.39","first-page":"31","article-title":"The prevalence of non-alcoholic fatty liver disease in patients of outpatient practice in the Russian Federation: the results of the study DIREG 2","volume":"25","author":"Ivashkin","year":"2015","journal-title":"Russian Journal of Gastroenterology, Hepatology, Coloproctology"},{"key":"2025073013320078000_7.1.e000368.40","first-page":"85","article-title":"[NONALCOHOLIC FATTY LIVER DISEASE: DIAGNOSTIC, SYMPTOMS, TREATMENT. GUIDELINES WERE APPROVED BY THE XV GASTROENTEROLOGICAL SCIENTIFIC SOCIETY OF RUSSIA IN 2015]","volume":"7","author":"Lazebnik","year":"2015","journal-title":"Eksp Klin Gastroenterol"},{"key":"2025073013320078000_7.1.e000368.41","first-page":"180","article-title":"A randomized controlled study of essential phospholipids (Essentiale capsules) in the treatment of fatty liver","volume":"13","author":"JH","year":"2000","journal-title":"Infect Dis Info"},{"key":"2025073013320078000_7.1.e000368.42","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(13)61365-3","article-title":"1366 beneficial influence of polyunsaturated phosphatidylcholine enhances functional liver condition and liver structure in patients with nonalcoholic steatohepatitis. Results of prolonged randomized blinded prospective clinical study","volume":"58","author":"Sas","year":"2013","journal-title":"J Hepatol"},{"key":"2025073013320078000_7.1.e000368.43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2019-000307","article-title":"Real-World comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia","volume":"6","author":"Maev","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"key":"2025073013320078000_7.1.e000368.44","first-page":"277","article-title":"Observation for curative effect of Essentiale in treatment of fatty liver caused by diabetes mellitus","volume":"15","author":"Yin","year":"2000","journal-title":"Med J Q Ilu"},{"key":"2025073013320078000_7.1.e000368.45","first-page":"1272","article-title":"Clinical observation on polyene phosphatidyl choline and metformin in the treatment of type 2 diabetes and non-alcoholic fatty liver disease","volume":"23","author":"Sun","year":"2008","journal-title":"Clin Focus"},{"key":"2025073013320078000_7.1.e000368.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(01)00297-2"},{"key":"2025073013320078000_7.1.e000368.47","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-018-0843-6","article-title":"Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal","volume":"18","author":"Pardhe","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"2025073013320078000_7.1.e000368.48","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-2-65"},{"key":"2025073013320078000_7.1.e000368.49","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2006.081257"},{"key":"2025073013320078000_7.1.e000368.50","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.3.701"},{"key":"2025073013320078000_7.1.e000368.51","doi-asserted-by":"crossref","unstructured":"Varganova DL , Pavlov CS , Casazza G , et al . Essential phospholipids for people with non-alcoholic fatty liver disease. Cochrane Database Syst Rev 2019;67.doi:10.1002\/14651858.CD013301","DOI":"10.1002\/14651858.CD013301"},{"key":"2025073013320078000_7.1.e000368.52","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1734-1140(11)70576-X","article-title":"Activity of essential phospholipids (EPL) from soybean in liver diseases","volume":"63","author":"Gundermann","year":"2011","journal-title":"Pharmacol Rep"},{"key":"2025073013320078000_7.1.e000368.53","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11120676","article-title":"Synergy of Phospholipid-Drug formulations significantly deactivates profibrogenic human hepatic stellate cells","volume":"11","author":"Valentino","year":"2019","journal-title":"Pharmaceutics"},{"key":"2025073013320078000_7.1.e000368.54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1994.tb00915.x"},{"key":"2025073013320078000_7.1.e000368.55","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840120621"},{"key":"2025073013320078000_7.1.e000368.56","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(94)95023-7"},{"key":"2025073013320078000_7.1.e000368.57","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(96)80147-4"},{"key":"2025073013320078000_7.1.e000368.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.01.025"},{"key":"2025073013320078000_7.1.e000368.59","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cbf.657","article-title":"Hepatic and pancreatic effects of polyenoylphosphatidylcholine in rats with alloxan-induced diabetes","volume":"14","author":"Buko","year":"1996","journal-title":"Cell Biochem Funct"},{"key":"2025073013320078000_7.1.e000368.60","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0022-2275(20)33501-X","article-title":"Oxidation of LDL in baboons is increased by alcohol and attenuated by polyenylphosphatidylcholine","volume":"40","author":"Navder","year":"1999","journal-title":"J Lipid Res"},{"key":"2025073013320078000_7.1.e000368.61","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1527328"},{"key":"2025073013320078000_7.1.e000368.62","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2298\/VSP150514093P","article-title":"Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound","volume":"73","author":"Petrovi\u0107","year":"2016","journal-title":"Vojnosanit Pregl"},{"key":"2025073013320078000_7.1.e000368.63","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3126\/jcmsn.v13i2.17773","article-title":"Lipid profile in different grades of ultrasonic non-alcoholic fatty liver disease","volume":"13","author":"Bhusal","year":"2017","journal-title":"J Coll Med Sci-Nepal"},{"key":"2025073013320078000_7.1.e000368.64","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3390\/jcm7110378","article-title":"Remnant lipoprotein cholesterol and cardiovascular and cerebrovascular events in patients with non-alcoholic fatty liver disease","volume":"7","author":"Pastori","year":"2018","journal-title":"J Clin Med"},{"key":"2025073013320078000_7.1.e000368.65","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25762"},{"key":"2025073013320078000_7.1.e000368.66","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/hep4.1241","article-title":"Among patients with NAFLD, treatment of dyslipidemia does not reduce cardiovascular mortality","volume":"2","author":"Shahab","year":"2018","journal-title":"Hepatol Commun"},{"key":"2025073013320078000_7.1.e000368.67","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50229"},{"key":"2025073013320078000_7.1.e000368.68","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(05)80350-2"},{"key":"2025073013320078000_7.1.e000368.69","doi-asserted-by":"crossref","first-page":"071","DOI":"10.1055\/s-2001-12930","article-title":"Imaging of hepatic steatosis","volume":"21","author":"Siegelman","year":"2001","journal-title":"Semin Liver Dis"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2019-000368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:32:15Z","timestamp":1753907535000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2019-000368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3,26]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/bmjgast-2019-000368"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2019-000368","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}